NCT00519467View on ClinicalTrials.gov

Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Malaria
Interventions
DRUG

Chlorproguanil-dapsone-artesunate (CDA)

Trial Locations (2)

30096,BLANTYRE 3

GSK Investigational Site, Blantyre

Unknown

GSK Investigational Site, Banjul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00519467 - Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria | Biotech Hunter | Biotech Hunter